

Clinical Trial Sites Overview

Q1 2023

Table of Contents


- I Market Update**
- II Clinical Trial Site Landscape**
- III Harris Williams Overview**

Clinical Trials Overview

Discovering and developing safe and effective pharmaceuticals is a challenging undertaking that can take 10+ years and \$2+ billion.

- › Clinical trials are research studies to test potential treatments in volunteers for efficacy and safety ahead of receiving approval for wider use in the general population
 - › Physician investigators initially enroll volunteers or patients into small pilot studies, and subsequently conduct progressively larger-scale comparative studies
- › Clinical trials are a key research step in the process of advancing medical knowledge and patient care, as they are a key step in discovering and testing new treatments or preventive measures for diseases with a drug, medical device, or biologic, such as a vaccine, blood product, or gene therapy


ROLE OF CLINICAL TRIALS WITHIN THE DRUG DEVELOPMENT PROCESS



Clinical Trial Sites Value Chain

Site management activities may be performed by trial sponsors, CROs, or SMOs at multiple site locations.

POTENTIAL STAKEHOLDERS FOR SITE OPERATORS



Trials utilize multiple sites and potentially one or more SMOs. Sites may include a combination of academic and commercial sites


- › **Site management** activities may be performed by the industry trial sponsors, contract research organizations (CROs), site management organizations (SMOs), or a combination of those stakeholders
 - › Outsourcing these services allows trial sponsors to operate with a lower cost base
 - › Site management activities include:
 - › Country / site selection
 - › Regulatory submissions
 - › Site initiation, monitoring, and coordination
 - › Data management
- › **Site-specific activities** are fully outsourced by trial sponsors and are undertaken by individual or networks of commercial or academic sites
 - › These activities have always been fully outsourced in order to ensure trial sponsors have access to patients; high capital requirements and potential conflicts of interest are also a factor
 - › Site-specific activities include:
 - › Patient recruitment, retention, and management
 - › Trial administration
 - › Data capture
- › Patient recruitment can be undertaken both at a site-specific level or centrally (the latter usually involving a PRO¹)
 - › SMOs will also provide centralized coordination for all their sites involved in each trial

Clinical Research Sites' Role in Clinical Trials

A typical sponsor/CRO will outsource clinical trial execution to multiple research sites to handle patient recruitment and retention, trial administration according to protocol, and data capture.




- › Clinical trials are complex processes, and outsourcing the execution of the trial promotes efficiencies throughout the process and enables sponsors to get their asset into the market faster
 - › Site-specific activities include patient recruitment, enrollment, retention and management, trial administration, and data capture
 - › Multi-site businesses, vs. single sites, offer expedited study start up and recruitment, de-risk project times due to integrated systems, offer a single point of contact for contracting, and have uniform SOPs that all increase the predictability of performance on trials
- › Sponsors and CROs focus on the design of protocols and the patient requirements needed, as well as performing monitor visits to ensure compliance and assess outcomes of the study

ROLE OF SITE BUSINESSES IN CLINICAL TRIAL PROCESS




Trends in Clinical Research Sites (3 Key Growth Drivers)

The clinical research site market is well-positioned for sustained growth, driven by several favorable trends and growth drivers.

Growth Driver 1	Recent Historical Growth in Pre-Clinical Assets Driving Near-Term Phase I - III Studies		<ul style="list-style-type: none"> › The U.S. pre-clinical pipeline has grown ~9% since 2015, compared to ~2%-3% historically ¹. › Steady historical growth in pharmaceutical R&D spend expected to continue
Growth Driver 2	Despite Recent Slow Down in Funding, Many Biotechs Have Strong Cash Positions to Fund R&D		<ul style="list-style-type: none"> › Biotech funding has significantly slowed in the past 12 months, but many investors believe there will be a near-term recovery › The most recent cycle has resulted in ~60% of biotech companies currently holding in excess of 12 months of cash runway
Growth Driver 3	Increasing Trial Complexity Driving Growth in Revenue per Trial		<ul style="list-style-type: none"> › Increasing complexity of clinical trials drives growth in costs to run sites and increases the demand for multi-site clinical trial site businesses who can meet the demands of complex recruiting needs

TOTAL U.S. CLINICAL TRIAL SITE MARKET ²

For the years ended and ending December 31, 2020-2025P
(\$ in billions)



1. Source: HealthAdvances
2. Ibid.


Growth Driver 1: Recent Historical Growth in Pre-clinical Assets

Accelerating growth in pre-clinical assets over the past 5-6 years is fueling growth in clinical trial activity.

- › Growth in pre-clinical assets translates directly into the overall growth of the clinical trial market as products move into clinical trials after an average of ~3-4 years of pre-clinical development
 - › The recent cycle in biotech and pharma investment has resulted in supportive cash positions companies
 - › Innovations have driven clinical development in new drug delivery technologies
 - › The current bolus in pre-clinical investment is expected to translate to Phase III clinical trial growth in the next few years
- › U.S. clinical trials expected to grow at a CAGR of 3.5% through 2025 ⁴.


PRE-CLINICAL DRUG PIPELINE ⁵

For the years ended and ending December 31, 2005-2020
(Number of Programs in Pipeline)



TOTAL U.S. CLINICAL TRIALS ⁶

For the years ended and ending December 31, 2015-2025P
(Number of U.S. Clinical Trials)



4. Source: HealthAdvances

5. Ibid.

6. Ibid.


Growth Driver 2: Funding Cycle Has Bolstered Cash Position for Many Biotechs

The current biotech funding cycle is approaching the longest observed downward trend; however, investor sentiment is cautiously optimistic, and outsourced spending is expected to remain elevated as companies seek to control costs.

- › Continued clinical trial growth is being sustained by the healthy balance sheets of pharma and biotech companies, increases in pre-clinical development, and recent validation of new technologies (e.g., mRNA) that can move into the clinic
 - › The 2020-2021 IPO and follow-on public offering boom provided a robust (and cost-efficient) backdrop to raise funds and support ongoing development
 - › Though the current funding cycle is approaching the longest observed downtrend, many expect capital markets to move swiftly when funding thaws
- › Trials are becoming more complex, driving upticks in enrollment requirements, the number of sites needed to complete a trial, the number of protocols needed, and regulatory requirements for more diverse patient populations
 - › With rising R&D costs and the funding cycle trough, pharma sponsors look to leverage CROs and multi-site clinical research site platforms to manage larger and more complex trials


EQUITY CAPITAL FUNDING IN BIOPHARMA ⁷

Rolling-Three-Year Biopharma Equity Investments
(\$ in billions)



GLOBAL CLINICAL R&D SPEND FORECAST ⁸

Global clinical R&D spend for the years ended and ending December 31, 2016-2026P
(\$ in billions)



Growth Driver 3: Increasing Trial Complexity Driving Growth in Revenue per Trial

Revenue per trial growth has accelerated in recent years as protocols become more complex, sponsors and CROs are managing more sites per trial, and sponsors seek diversity in difficult-to-access patient populations.

PROTOCOL COMPLEXITY

- › The average number of endpoints per protocol has increased by 6% on average each year since 2003 ⁹.
- › Sites with the ability to successfully execute complex protocols will continue to be in high demand

INCREASE IN SITES ENROLLED

- › Average sites per trial increased by ~4-5% every year between 2005 and 2019 ¹⁰.
- › More sites are needed in order to match increased patient enrollment and geographic diversity needs

MODEST GAINS IN PATIENT ENROLLMENT


- › Average patient enrollment fell from 2005 to 2010 but has made modest gains in the past 10 years
- › There is also modest growth revenue per patient, projected at 2.5%+ CAGR through 2025, which will drive revenue per trial for site businesses ¹¹.

DEMANDS FOR PATIENT DIVERSITY

- › In 2011, only 1% of trial participants were Hispanic, but by 2016, 18% of trial participants were Hispanic ¹².
- › Clinical trials are increasingly utilizing diverse patient populations across multiple geographies to prepare to meet the future of regulatory requirements

INCREASE IN NUMBER OF AVERAGE SITES PER TRIAL ¹³.


For the years ended December 31, 2005-2019
(Average Number of Sites Per Phase III Trial)



Driving growth in revenue per trial through increases in average number of sites per trial and average outcomes per trial

INCREASE IN NUMBER OF AVERAGE OUTCOMES PER TRIAL ¹⁴.

For the years ended December 31, 2005-2019
(Average Number of Outcomes Per Phase III Trial)



The Rise of Virtual and Hybrid Clinical Trials

Industry experts expect few truly virtual trials and instead foresee most trials employing decentralized, hybrid virtual trial methods to supplement brick-and-mortar sites.

- › Virtual trials include any aspect of the trial process that is decentralized and can be completed from any location, which can drive improved access and patient recruiting for clinical trials
 - › Currently, clinical research providers are utilizing available virtual tools for interoperability efficiencies, such as eConsent, and in the near future, more aspects of trials will have virtual capabilities, including sophisticated data capture
- › Virtual components of clinical trials will serve as a growth driver and a competitive advantage for businesses with the ability to efficiently implement the infrastructure to execute on a hybrid trial site model
 - › A hybrid trial site model of in-person and virtual solutions is expected to gain traction and grant patients flexibility when attending their protocol visits, ultimately driving their participation and increasing patient retention
 - › Over the next few years, integration of virtual clinical trial capabilities is likely to increase, and the industry is expected to start incorporating virtual / remote technologies into ~10%-15% of total clinical trials ¹⁵.


BUILDING A TOOLKIT OF DECENTRALIZED METHODS...



- | | |
|-----------------|---------------------|
| › eConsent | › Video Visits |
| › Home Health | › Remote Monitoring |
| › Local Labs | › Central Site |
| › Local Imaging | › Home Drug Supply |

...TO FACILITATE THE HYBRID VIRTUAL TRIAL EXPERIENCE

The COVID-19 pandemic catalyzed the adoption of virtual capabilities in clinical trials. While going fully virtual is highly unlikely, hybrid models are expected to gain traction.



- › Patient still travels to sites for some in-person services
- › Sites employ virtual solutions to limit burden on patients (e.g., reduced visits)

Brick-and-Mortar Clinical Trial Sites Remain Essential Despite the Rise of Hybrid and Virtual Trials

Importantly, clinical trial sites own the patient relationship and will play an integral role in working with vendors to employ and accommodate virtual methods and new technologies.



TRADITIONAL CLINICAL TRIALS

- › Traditional clinical trials may be conducted at dedicated (e.g., independent sites, SMOs) and non-dedicated trial sites (e.g., AMCs, physicians' offices)
- › Site-specific activities include patient recruitment, retention and management, trial administration, and data capture



TECH-ENABLED CLINICAL TRIALS

- › SMO partners and other clinical trial participants are beginning to weave in additional tech capabilities to address the rising complexity of clinical trials
- › Integrated and streamlined trial activities (e.g., endpoint collection, administration)
- › Digitized and automated workflows (e.g., patient recruitment, monitoring)




DECENTRALIZED / HYBRID CLINICAL TRIALS

- › Decentralized clinical trials (DCT) may feature:
 - › Tech to support patients who are remotely monitored
 - › Remote data collection through technology (e.g., virtual interface, remote monitoring/wearables) or via mobile clinicians
- › However, very few trials are fully decentralized; trials in this space typically feature components of DCT for a hybrid approach

Clinical trial sites ultimately own the patient relationship and therefore remain crucial to the success of clinical trial types

Levels of Site Integration across Trial Sites

Multi-site, dedicated clinical trial operators feature highest inter-site integration.



Strategic Models of Scaled Operators:

Therapeutic Area Specialists & Operational Executors

Traditionally, scaled operators focused on operational excellence or therapeutic area specialization; additional capabilities differentiate market participants.

Operational executors

- › Focus on sites that can run trials across a broad range of diseases, especially ones with high trial / patient volume and less complex trial protocols
- › Continuously expand TA coverage to ensure that the broadest range of trials is addressable
- › Emphasize operational excellence, availability of many sites able to serve each trial, and superior service and capabilities as key points of differentiation

Therapeutic area (TA) specialists

- › TA specialized sites sell an established track record of trial success, a high-science understanding of indication nuances, and access to specialized patient populations
- › Position the narrower site group as a more efficient option vs. academic medical centers or physicians' private practices
- › After establishing reputation in a TA, pursue opportunity to expand into adjacent indications for growth opportunities

Low

Specific therapeutic area focus

High

Specialized site-based capabilities

- › Select a niche capability required in certain trial protocols and acquire sites with similar features (e.g., surgical suites, Phase I inpatient facility, complex imaging, sleep equipment, telemetry, EEGs)
- › Develop a best-in-class supporting organization to position the sites as the go-to option for trials requiring those specific capabilities


Recruiting enablers

- › Focus on acquiring sites that have large databases for recruitment access to EMRs and deploy centralized recruitment and pre-screening
- › Incorporate sites that can reach specialized populations (e.g., demographic groups)
- › Establish best-in-class processes and partnerships to facilitate recruitment and retention and emphasize successful track record


Clinical Trial Site Business:

Industry Challenges and Critical Success Factors

Clinical trial sites with integrated operations have demonstrated the ability to overcome industry challenges and execute high-quality clinical trials.



CRITICAL SUCCESS FACTORS:




Opportunities Exist in a Highly Fragmented Market

The overall market for clinical trial site businesses is highly fragmented and poised for continued consolidation, with multi-site platforms or alliance networks accounting for only ~4% of total trial sites.

- › There are ~20,500 clinical trial sites in the U.S., with ~96% being single sites, which typically do not have the same access to patients as organized multi-site trial sites ¹⁶.
 - › A clinical trial site provider possessing multiple sites generally has improved recruitment capabilities as well as centralized support functions
- › Consolidation of the sector is in early innings, and is expected to accelerate in the coming years
 - › The market will continue to consolidate as pharmaceutical sponsors and CROs are increasingly looking to contract with fully owned, integrated models that provide a level of service, breadth of sites, and depth of therapeutic expertise that single sites or smaller networks cannot replicate
 - › Individual sites are increasingly unable to meet recruitment goals as studies continue to get more complex, giving providers of scale a significant competitive advantage
 - › Having a greater number of sites drives more effective patient recruitment, enrollment, and retention; this competitive advantage will accelerate the consolidation trend

CLINICAL RESEARCH SITE FRAGMENTATION



~59,000 unique clinical trial sites utilized in the U.S. between 2015 and 2020

~20,500 unique trial sites in the U.S. annually on average

533 clinical trial sites associated with Alliance Networks

177 owned and operated by multi-site clinical trial businesses

Scorecard for Realizing a Premium Valuation

There are several key valuation drivers to focus on for achieving a premium value for a clinical trial site business.











Valuation Driver	Valuation Impact	Key Question	Winning the Value Point
Backlog and Pipeline Visibility	 Low High	› What does current backlog/pipeline predict in terms of forward earnings based on historical record?	› Trial-by-trial backlog and pipeline conversion analysis over time, and coverage analysis on forward looking profitability
Margin Sustainability	 Low High	› Did COVID-19 vaccine work increase margins in a way that is unsustainable long-term?	› Analysis of historical and projected margins, gross margins by trial during budgeting vs actual site-level margin
Therapeutic Area Concentration Risk	 Low High	› How has the platform weathered changes in demand and is the portfolio diverse enough?	› Historical revenue and projected backlog/pipeline analysis by TA, including rev. per patient per visit and volume per trial
Principal Investigator “Key Person” Risk	 Low High	› Is there concentration risk in the PI base that could adversely impact the business?	› PI database and loop covering historical retention, compensation model, ownership (if any), and age/planned retirements
Business Development Capabilities	 Low High	› Is there an opportunity to increase sites per study through cross-selling/strategic account management?	› Historical and projected sites per study analysis, contract negotiation analysis
Acquisition Story	 Low High	› What is the track record and current outlook to acquire and grow additional sites?	› Pre- and post-acquisition performance analysis, purchase price multiple analysis, M&A pipeline
Patient Enrollment Capabilities	 Low High	› Has the platform built a better mousetrap to offer value to sponsors by over-enrolling studies?	› Patient funnel, actual versus targeted enrollment (internal and sponsor/CRO targets)
De Novo Story	 Low High	› Are there predictable investment economics and returns on new sites?	› De novo ramp and maturity analysis
Decentralized Trials	 Low High	› Will revenue per patient be impacted by future DCT methods being increasingly adopted?	› Excerpts from industry conversations and an overview deck of management’s view to build/buy/partner for each DCT method

Table of Contents

- I Market Update
- II Clinical Trial Site Landscape
- III Harris Williams Overview

Flurry of Activity in Clinical Trial Sites

There has been significant private equity activity in the clinical trial site space in recent years, with ten notable platforms acquired or created since January 2021, and consolidation is expected to continue.



Platform Tuck-Ins

Headlands Clinical Research Nov 2019 OKANAGAN CLINICAL TRIALS Nov 2019 Centex Studies Nov 2019 JEM Jul 2020 TORONTO MEMORY PROGRAM Jul 2020 ARTEMIS Feb 2021 SUMMIT RESEARCH May 2021 PRA Peninsula Research Associates Jun 2021	CenExel CenExel ACMR Nov 2018 CenExel ACT Feb 2019 CenExel BICA Nov 2019 CenExel CNR Jan 2022 CITRIALS Mar 2021 FORCARE Aug 2021 AVRI Sep 2021 ADVANCED MEMORY RESEARCH INSTITUTE OF NJ Sep 2021 MOVEMENT DISORDERS CENTER Jan 2022 Research Atlanta Apr 2022 Apex Jun 2022	ERG Finger Lakes Clinical Research Apr 2019 Lotus Nov 2021 Richmond Behavioral Associates Mar 2020 CNS Nov 2021 Ohio Clinical Trials, Inc. Jun 2022 Velocity² Clarity Jul 2021 VITALINK Sep 2021 MedPharma Sep 2022 NRI Sep 2021 EGIN RESEARCH Nov 2022 TTRICR Feb 2022 Clinical Research Hamburg Jul 2022 MERIDIAN Dec 2022	NZCR ACS Sep 2020 TST Sep 2020	Elligo clineedge Sep 2021	Pinnacle STRI Jan 2023
			Flourish CTT Clinical Trials of Texas Jul 2021 Keystone Oct 2022 ExcelMedical Oct 2021 BUNDSIDE RESEARCH Dec 2022	Alcanza COASTAL CAROLINA RESEARCH CENTER Sep 2022 ACTIVMED Sep 2022 BCT Box on Clinical Trials Sep 2022 QUEST Sep 2022	PCRN LAKELAND CLINICAL TRIALS GROUP Oct 2021 SOUTHERN TRIALS RESEARCH Oct 2021

Note: 2. Velocity add-ons include only those under GH0's ownership

Competitive Landscape

TO DISCUSS COMPETITIVE LANDSCAPE

PLEASE CONTACT:

hclspharmaserviceteam@harriswilliams.com

Table of Contents

- I Market Update
- II Clinical Trial Site Landscape
- III Harris Williams Overview

HW Harris Williams / GLOBAL M&A ADVISOR

Harris Williams is a global investment bank specializing in M&A advisory services. Clients worldwide rely on us to help unlock value in their business and turn ambitious goals into reality. We approach every engagement with boundless collaboration, pooling expertise and relationships across industries and geographies to uncover the unique story of each company.

Deep Industry Experience



Aerospace, Defense
& Government Services



Business
Services



Consumer



Energy, Power
& Infrastructure



Healthcare &
Life Sciences



Industrials



Technology



Transportation
& Logistics

70% Revenue from repeat clients

83% Managing directors promoted from within the firm

30+ Year history



Unmatched Healthcare & Life Sciences Experience

The proof is in the results – HW has built the market's leading healthcare & life sciences M&A practice.

Dedicated Team with a Proven Track Record of Results

60+


Dedicated HCLS professionals

5

HW HCLS Offices, with presence in
US and Europe

~\$500M

Average Enterprise Value



Healthcare & Life Sciences Group Verticals

Outsourced Pharma Services

HCIT

Providers

Medical Products and Devices

Payors & Payor Services

Life Sciences Tools

Clinical Lab Services

Pharmacy

**Outsourced
Provider Services**
**Provider, Pharma,
& Device
Distribution**

Highly Relevant Pharma Services Experience

HW has a leading pharma services franchise and maintains active dialogue with the most relevant strategic and financial investors.

- HW's recent deal experience provides additional insight into key investors' playbooks and hot buttons while reinforcing our thought leadership with practical experience

2019 – 2023 Pharma Services Deals

Engaged Client A Commercialization Services	Engaged Client B Clinical Trial Site Platform	Engaged Client C Pharma IT	PHARMALEX <small>CONFIDENCE IN YOUR COMPANY</small> a portfolio company of AUCTUS has been acquired by AmerisourceBergen	celerion <small>Translating Evidence to Medicine</small> a portfolio company of SQUARE CAPITAL has been acquired by H.I.G. CAPITAL	 a portfolio company of NAVIMED CAPITAL has been acquired by OPEN HEALTH a portfolio company of astorg.
JordiLabs has been acquired by RQM+ a portfolio company of LINDEN	STAXS* <small>COMMERCIALIZATION CONTROL EXPERTS</small> a portfolio company of Silverfleet has been acquired by HANIEL	medicalknowledgegroup. a portfolio company of SQUARE CAPITAL has been acquired by novo holdings	cerberus has acquired Clinical Trial Site Management Platform	RQM+ <small>a portfolio company of</small> DFW CAPITAL PARTNERS Chartwell Investments <small>ENTREPRENEUR & FOUNDER CAPITAL</small> has been acquired by LINDEN	Velocity <small>CLINICAL RESEARCH</small> a portfolio company of NAVIMED CAPITAL has been acquired by GHO++ CAPITAL
KANTAR HEALTH+ a portfolio company of BainCapital PRIVATE EQUITY has been acquired by Cerner	ALTASCIENCES a portfolio company of Andur Group has been acquired by novo holdings	KNOX-LANE has made a strategic investment in fingerprint	wcg <small>WINDROSE CAPITAL PARTNERS</small> a portfolio company of ARSENAL CAPITAL PARTNERS has been recapitalized by LGP LEONARD GREEN & PARTNERS	medicalknowledgegroup. a portfolio company of WINDROSE CAPITAL PARTNERS has been recapitalized by SQUARE CAPITAL	ERG a portfolio company of DFW CAPITAL PARTNERS has been acquired by LINDEN

Thought Leadership in Pharma Services

Return on Innovation, Part 1: Commercialization Services <small>ARTICLE – OCTOBER 1, 2018</small>
Return on Innovation, Part 2: Contract Research Organizations <small>ARTICLE – MAY 31, 2019</small>
Return on Innovation, Part 3: Pharmaceutical Safety and Risk Management <small>ARTICLE – OCTOBER 29, 2019</small>
Return on Innovation, Part 4: Contract Development and Manufacturing Organizations (CDMOs) <small>ARTICLE – SEPTEMBER 14, 2021</small>
Return on Innovation, Part 5: Real-World Evidence <small>ARTICLE – DECEMBER 15, 2021</small>
Return on Innovation, Part 6: Clinical Trial Sites <small>ARTICLE – JUNE 9, 2022</small>
Return on Innovation, Part 7: Outsourced Pharma Services: Differentiation Via Data <small>ARTICLE – JANUARY 30, 2023</small>

HarrisWilliams.com

Select Buyers Engaged on Recent Deals

Get in Touch

HW Harris Williams / GLOBAL M&A ADVISOR

8 INDUSTRY GROUPS

With Robust Experience
Across the Globe

3 DECADES

of Providing Award-Winning
M&A Advisory Services

1 UNIFIED TEAM

Bringing Firmwide Dedication
to Every Engagement



Paul Hepper

Managing Director
Healthcare & Life Sciences
Group

+1 804.887.6026
phepper@harriswilliams.com



Cheairs Porter

Managing Director
Healthcare & Life Sciences
Group

+1 804.536.3426
cporter@harriswilliams.com



Geoffrey Smith Jr.

Managing Director
Healthcare & Life Sciences
Group

+1 804.647.5926
gsmith@harriswilliams.com



Lucas Scholl

Vice President
Healthcare & Life Sciences
Group

+1 415.416.0766
lscholl@harriswilliams.com

HW Disclosure/Disclaimer Page

Investment banking services are provided by Harris Williams LLC (“Harris Williams”). Harris Williams is a registered broker-dealer and member of FINRA and SIPC. Harris Williams & Co. Ltd is a private limited company incorporated under English law with its registered office at 8th Floor, 20 Farringdon Street, London EC4A 4AB, UK, registered with the Registrar of Companies for England and Wales, registration number 07078852. Harris Williams & Co. Ltd is authorized and regulated by the Financial Conduct Authority. Harris Williams & Co. Corporate Finance Advisors GmbH is registered in the commercial register of the local court of Frankfurt am Main, Germany, under HRB 107540. The registered address is Bockenheimer Landstrasse 33-35, 60325 Frankfurt am Main, Germany (email address: hwgermany@harriswilliams.com). Geschäftsführers/Directors: Jeffery H. Perkins, Paul Poggi, VAT No. DE321666994. Harris Williams is a trade name under which Harris Williams LLC, Harris Williams & Co. Ltd and Harris Williams & Co. Corporate Finance Advisors GmbH conduct business.

The information and views contained in this content have been prepared in part by Harris Williams. This content does not purport to be comprehensive or to contain all the information that a recipient may need in order to evaluate any investment or potential transaction. This content is not a research report, as such term is defined by applicable law and regulations, and is provided for informational purposes only. Any and all information, including estimates, projections and other forward-looking statements, presented in this document may involve various assumptions and significant elements of subjective judgment and analysis that may or may not be correct. Harris Williams has not independently verified, and neither Harris Williams nor any other person will independently verify, any of the information, estimates, projections or forward-looking statements contained herein or the assumptions on which they are based. The information contained in this document is made as of the date hereof unless stated otherwise. Harris Williams does not expect to update or otherwise revise this document nor provide any additional information, nor correct any inaccuracies herein which may become apparent.

This content is intended for institutional use only and should not be relied upon by retail investors or members of the general public. The information contained herein is believed by Harris Williams to be reliable but Harris Williams makes no representation or warranty as to the accuracy or completeness of such information, and information contained herein that is based on material prepared by others may involve significant elements of subjective judgment and analysis which may or may not be correct. Opinions, estimates and projections contained herein constitute Harris Williams’ judgment and are subject to change without notice.

This content is not to be construed as investment advice an offer to buy or sell or a solicitation of an offer to buy or sell any financial instruments or to participate in any particular transaction, nor shall this content form the basis of any contract. It does not constitute and should not be construed as an endorsement or recommendation of any entities’ products or services.

No part of this material may be copied or duplicated in any form or by any means, or redistributed, without Harris Williams’ prior written consent.